Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations

被引：15

作者：

Grass, George Daniel ^{[1
]}

Mills, Matthew N. ^{[2
]}

Ahmed, Kamran A. ^{[1
]}

Liveringhouse, Casey L. ^{[2
]}

Montejo, Michael J. ^{[1
]}

Robinson, Timothy J. ^{[1
]}

Chavez, Julio C. ^{[3
]}

Harrison, Louis B. ^{[1
]}

Kim, Sungjune ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA

[2] Univ S Florida, Coll Med, Tampa, FL USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

来源：

LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 04期

关键词：

Radiation; double hit or triple hit lymphoma; molecular genetics; NON-HODGKIN-LYMPHOMA; RADIATION-THERAPY; RESPONSE ASSESSMENT; INVOLVED-FIELD; R-CHOP; RITUXIMAB; EXPRESSION; SURVIVAL; MYC; CLASSIFICATION;

D O I：

10.1080/10428194.2018.1506586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

We investigated whether adding radiation (RT) to systemic therapy improved outcomes in early stage diffuse large B-cell lymphoma (DLBCL) patients with or without double- or triple-hit lymphoma (DHL/THL) biology. This analysis included 183 patients profiled with fluorescent in situ hybridization (FISH) for alterations in MYC, BLC2, and/or BCL6. A total of 146 (80%) were non-DHL/THL, 27 (15%) were DHL, and 10 (6%) were THL. Systemic therapy without RT resulted in inferior freedom from relapse (FFR) (HR: 2.28; 95% CI, 1.10-4.77; p = .02). The median FFR for non-DHL/THL was not reached and was 33 and 22.3 months for DHL and THL, respectively; p < .001. Low-risk (R-IPI <2) DHL/THL patients treated with rituximab-based therapy had 3-year FFR rates of 11% and 71% for systemic therapy without and with RT, respectively; p = .04. No differences in overall survival were observed between the treatment groups. Treatment intensification with RT may improve early stage DHL/THL outcomes.

引用

页码：886 / 893

页数：8

共 36 条

[1]

The Spectrum of Double Hit Lymphomas [J].

Abramson, Jeremy S. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (06) :1239-+

[2]

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[3]

Double-hit B-cell lymphomas [J].

Aukema, Sietse M. ;

Siebert, Reiner ;

Schuuring, Ed ;

van Imhoff, Gustaaf W. ;

Kluin-Nelemans, Hanneke C. ;

Boerma, Evert-Jan ;

Kluin, Philip M. .

BLOOD, 2011, 117 (08) :2319-2331

[4]

Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].

Barrans, Sharon ;

Crouch, Simon ;

Smith, Alex ;

Turner, Kathryn ;

Owen, Roger ;

Patmore, Russell ;

Roman, Eve ;

Jack, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365

[5]

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group [J].

Barrington, Sally F. ;

Mikhaeel, N. George ;

Kostakoglu, Lale ;

Meignan, Michel ;

Hutchings, Martin ;

Mueeller, Stefan P. ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Fisher, Richard I. ;

Trotman, Judith ;

Hoekstra, Otto S. ;

Hicks, Rodney J. ;

O'Doherty, Michael J. ;

Hustinx, Roland ;

Biggi, Alberto ;

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3048-+

[6]

Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy Involved-Field Versus Involved-Node Radiotherapy [J].

Campbell, Belinda A. ;

Connors, Joseph M. ;

Gascoyne, Randy D. ;

Morris, W. James ;

Pickles, Tom ;

Sehn, Laurie H. .

CANCER, 2012, 118 (17) :4156-4165

[7]

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[8]

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study [J].

Copie-Bergman, Christiane ;

Cuilliere-Dartigues, Peggy ;

Baia, Maryse ;

Briere, Josette ;

Delarue, Richard ;

Canioni, Danielle ;

Salles, Gilles ;

Parrens, Marie ;

Belhadj, Karim ;

Fabiani, Bettina ;

Recher, Christian ;

Petrella, Tony ;

Ketterer, Nicolas ;

Peyrade, Frederic ;

Haioun, Corinne ;

Nagel, Inge ;

Siebert, Reiner ;

Jardin, Fabrice ;

Leroy, Karen ;

Jais, Jean-Philippe ;

Tilly, Helve ;

Molina, Thierry Jo ;

Gaulard, Philippe .

BLOOD, 2015, 126 (22) :2466-2474

[9]

ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma [J].

Dabaja, Bouthaina S. ;

Advani, Ranjana ;

Hodgson, David C. ;

Dhakal, Sughosh ;

Flowers, Christopher R. ;

Ha, Chul S. ;

Hoppe, Bradford S. ;

Mendenhall, Nancy P. ;

Metzger, Monika L. ;

Plastaras, John P. ;

Roberts, Kenneth B. ;

Shapiro, Ronald ;

Smith, Sonali M. ;

Terezakis, Stephanie A. ;

Winkfield, Karen M. ;

Younes, Anas ;

Constine, Louis S. .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (06) :610-620

[10]

German High-Grade Non-Hodgkin's Lymphoma Study Group, RIT COMB CHEM RAD TH

← 1 2 3 4 →